Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Weekly News Recap #Phispers
1. 4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide
2. Azd5363
1. Azd5363
2. 1143532-39-1
3. Azd-5363
4. Azd 5363
5. (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
6. 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
7. Wfr23m21ie
8. 4-piperidinecarboxamide, 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-
9. 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide
10. Unii-wfr23m21ie
11. Chembl2325741
12. Cc-638
13. Capivasertib?
14. 4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide
15. 4-piperidinecarboxamide, 4-amino-n-((1s)-1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-
16. Capivasertib (jan/usan)
17. Capivasertib [inn]
18. Capivasertib [jan]
19. Capivasertib [usan]
20. Capivasertib (azd5363)
21. Mls006011179
22. Capivasertib [who-dd]
23. Schembl390243
24. Gtpl7709
25. Azc5363
26. Dtxsid40150710
27. Ex-a285
28. Us10654855, Example 9
29. Bdbm443385
30. Mfcd22628785
31. Nsc764039
32. Nsc782347
33. Nsc799347
34. S8019
35. Zinc43204023
36. Akos027323693
37. Bcp9000365
38. Ccg-268989
39. Cs-1284
40. Db12218
41. Nsc-764039
42. Nsc-782347
43. Nsc-799347
44. Ncgc00345795-01
45. Ncgc00345795-04
46. Ac-32685
47. Hy-15431
48. Smr004702948
49. Bcp0726000111
50. A1387
51. Sw220158-1
52. D11371
53. J-514447
54. Q27074756
55. 0xz
56. 4-amino-n-((1s)-1-(4-chlorophenyl)-3-hydroxypropyl)-1- (1h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide
57. Alternative Route 1: (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
Molecular Weight | 428.9 g/mol |
---|---|
Molecular Formula | C21H25ClN6O2 |
XLogP3 | 1.7 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 6 |
Exact Mass | 428.1727518 g/mol |
Monoisotopic Mass | 428.1727518 g/mol |
Topological Polar Surface Area | 120 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 580 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of breast cancer , Treatment of prostate cancer
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Details:
Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor, is being investigated for PTEN-deficient de novo mHSPC in combination with abiraterone and ADT.
Lead Product(s): Capivasertib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Brand Name: Truqap
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 25, 2024
Lead Product(s) : Capivasertib,Abiraterone Acetate,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TRUQAP® (capivasertib) Phase 3 Shows Radiographic PFS Benefit in Prostate Cancer
Details : Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor, is being investigated for PTEN-deficient de novo mHSPC in combination with abiraterone and ADT.
Product Name : Truqap
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 25, 2024
Details:
Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of AKT1/2/3. It is being evaluated for the treatment of locally advanced or metastatic triple-negative breast cancer.
Lead Product(s): Capivasertib,Paclitaxel
Therapeutic Area: Oncology Brand Name: Truqap
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 18, 2024
Lead Product(s) : Capivasertib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CAPItello-290 Phase III: Truqap Plus Chemo in Advanced Triple-Negative Breast Cancer
Details : Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of AKT1/2/3. It is being evaluated for the treatment of locally advanced or metastatic triple-negative breast cancer.
Product Name : Truqap
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2024
Details:
Truqap (capivasertib) is a first-in-class AKT inhibitor approved in combination with fulvestrant for advanced HR-positive breast cancer treatment.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Brand Name: Truqap
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 29, 2024
Lead Product(s) : Capivasertib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Truqap Plus Faslodex Recommended for EU Approval in Advanced ER-positive Breast Cancer
Details : Truqap (capivasertib) is a first-in-class AKT inhibitor approved in combination with fulvestrant for advanced HR-positive breast cancer treatment.
Product Name : Truqap
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2024
Details:
Truqap (capivasertib) is an ATP-competitive inhibitor of all AKT isoforms, approved in combination with Faslodex (fulvestrant) for advanced HR-positive breast cancer treatment.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Brand Name: Truqap
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 27, 2024
Lead Product(s) : Capivasertib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Truqap Plus Faslodex Approved in Japan for Advanced HR-Positive Breast Cancer
Details : Truqap (capivasertib) is an ATP-competitive inhibitor of all AKT isoforms, approved in combination with Faslodex (fulvestrant) for advanced HR-positive breast cancer treatment.
Product Name : Truqap
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2024
Details:
Truqap (capivasertib) is a first-in-class ATP-competitive inhibitor of all three AKT isoforms, approved with Faslodex (fulvestrant) for advanced HER2-/HR+ breast cancer treatment.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Brand Name: Truqap
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: AstraZeneca
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 27, 2024
Lead Product(s) : Capivasertib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Chugai Obtains Approval for FoundationOne CDx as Diagnostic for Capivasertib in BC
Details : Truqap (capivasertib) is a first-in-class ATP-competitive inhibitor of all three AKT isoforms, approved with Faslodex (fulvestrant) for advanced HER2-/HR+ breast cancer treatment.
Product Name : Truqap
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2024
Details:
Truqap, a first-in-class AKT inhibitor, discovered by AstraZeneca subsequent to its collaboration with Astex, recently approved by FDA in combination with Faslodex, for treatment for adult patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Brand Name: Truqap
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: AstraZeneca
Deal Size: $275.0 million Upfront Cash: $5.0 million
Deal Type: Collaboration November 22, 2023
Lead Product(s) : Capivasertib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : AstraZeneca
Deal Size : $275.0 million
Deal Type : Collaboration
Otsuka's U.K. subsidiary Astex Has Third Approval Success in a Drug Discovery Collaboration - Ast...
Details : Truqap, a first-in-class AKT inhibitor, discovered by AstraZeneca subsequent to its collaboration with Astex, recently approved by FDA in combination with Faslodex, for treatment for adult patients with HR-positive, HER2-negative, locally advanced or met...
Product Name : Truqap
Product Type : Other Small Molecule
Upfront Cash : $5.0 million
November 22, 2023
Details:
Truqap (capivasertib), a first in class, oral targeted inhibitor of the cancer-driving protein AKT, was discovered by AstraZeneca subsequent to its discovery collaboration with Astex.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Brand Name: Truqap
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: AstraZeneca
Deal Size: $275.0 million Upfront Cash: $5.0 million
Deal Type: Collaboration November 20, 2023
Lead Product(s) : Capivasertib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : AstraZeneca
Deal Size : $275.0 million
Deal Type : Collaboration
Details : Truqap (capivasertib), a first in class, oral targeted inhibitor of the cancer-driving protein AKT, was discovered by AstraZeneca subsequent to its discovery collaboration with Astex.
Product Name : Truqap
Product Type : Other Small Molecule
Upfront Cash : $5.0 million
November 20, 2023
Details:
Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of all three AKT isoforms (AKT1/2/3). It is approved in combination with fulvestrant for the treatment of patients with advanced HR-positive breast cancer.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Brand Name: Truqap
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 20, 2023
Lead Product(s) : Capivasertib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for AstraZeneca’s Truqap™ (capi...
Details : Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of all three AKT isoforms (AKT1/2/3). It is approved in combination with fulvestrant for the treatment of patients with advanced HR-positive breast cancer.
Product Name : Truqap
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2023
Details:
Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of all three AKT isoforms (AKT1/2/3). It is approved in combination with fulvestrant for the treatment of patients with advanced HR-positive breast cancer.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Brand Name: Truqap
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 17, 2023
Lead Product(s) : Capivasertib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TRUQAP™ (capivasertib) Plus Fulvestrant Approved in The Us for Patients with Advanced HR-Positiv...
Details : Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of all three AKT isoforms (AKT1/2/3). It is approved in combination with fulvestrant for the treatment of patients with advanced HR-positive breast cancer.
Product Name : Truqap
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2023
Details:
AZD5363 (capivasertib) is an investigational orally and potent, adenosine triphosphate (ATP)-competitive inhibitor of all three AKT isoforms (AKT1/2/3) and in combination with Faslodex granted Priority Review in the US for patients with advanced HR-positive breast cancer.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Brand Name: Truqap
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 12, 2023
Lead Product(s) : Capivasertib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZD5363 (capivasertib) is an investigational orally and potent, adenosine triphosphate (ATP)-competitive inhibitor of all three AKT isoforms (AKT1/2/3) and in combination with Faslodex granted Priority Review in the US for patients with advanced HR-posit...
Product Name : Truqap
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2023
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
27
PharmaCompass offers a list of Capivasertib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Capivasertib manufacturer or Capivasertib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Capivasertib manufacturer or Capivasertib supplier.
PharmaCompass also assists you with knowing the Capivasertib API Price utilized in the formulation of products. Capivasertib API Price is not always fixed or binding as the Capivasertib Price is obtained through a variety of data sources. The Capivasertib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Capivasertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Capivasertib, including repackagers and relabelers. The FDA regulates Capivasertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Capivasertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Capivasertib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Capivasertib supplier is an individual or a company that provides Capivasertib active pharmaceutical ingredient (API) or Capivasertib finished formulations upon request. The Capivasertib suppliers may include Capivasertib API manufacturers, exporters, distributors and traders.
click here to find a list of Capivasertib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Capivasertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Capivasertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Capivasertib GMP manufacturer or Capivasertib GMP API supplier for your needs.
A Capivasertib CoA (Certificate of Analysis) is a formal document that attests to Capivasertib's compliance with Capivasertib specifications and serves as a tool for batch-level quality control.
Capivasertib CoA mostly includes findings from lab analyses of a specific batch. For each Capivasertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Capivasertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Capivasertib EP), Capivasertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Capivasertib USP).